ORIC Pharma Collaborates With Pfizer For Phase 2 Study Of OR

NEW YORK CITY (dpa-AFX) - ORIC Pharmaceuticals Inc. (ORIC) said that it has reached a clinical development collaboration with Pfizer for a potential phase 2 study of ORIC-533 in multiple myeloma.ORIC

Related Keywords

Jeff Settleman , Pfizer , Pharmaceuticals Inc , Oncology Research Development , Chief Scientific Officer , Oncology Research , Including Pfizer , Foric , Dharma , Ollaborates , Ith , Hase , Study , Multiple , Myeloma , Stock ,